LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

20.02 3.78

Buy Sell

Overview

Share price change

24h

Current

Min

19.22

Max

20.32

Key metrics
By Trading Economics
Income	102K -128M
EPS	-0.69
Employees	507
EBITDA	-9.8M -135M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+90.45% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-4.1M 3B
Previous open	16.24
Previous close	20.02

News Sentiment

By Acuity

76%

24%

307 / 344 Healthcare

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 May 2026, 16:52 UTC

Major News Events

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 May 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q Rev $1.76B >SQM

26 May 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q EPS $1.28 >SQM

26 May 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 May 2026, 21:54 UTC

Earnings

Webco Industries 3Q EPS $11.61 >WEBC

26 May 2026, 21:54 UTC

Earnings

Webco Industries 3Q Sales $179.6M >WEBC

26 May 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 May 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 May 2026, 20:58 UTC

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 May 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 May 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 May 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 May 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 May 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 May 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 May 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 May 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 May 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 May 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 May 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 May 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 May 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 May 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

26 May 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 May 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 May 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

90.45% upside

12 Months Forecast

Average 35.5 USD 90.45%

High 42 USD

Low 23 USD

Based on 13 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

307 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.